Dolutegravir/rilpivirine for the treatment of HIV-1 infection

Abstract

Ellen Dowers,1 Francis Zamora,1 Lydia Aoun Barakat,2 Onyema Ogbuagu2 1Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT, USA; 2Yale AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA Abstract: Much progress has been made in the development of antiretroviral therapies (ARTs) for HIV-1 infection. Beginning a little over a decade ago, single tablet combination regimens (STRs) became available, and subsequently, newer STR formulations with improved safety profiles have emerged. Recently, there is a growing interest in regimen simplification with the primary goal of further reducing long-term toxicities of ART and improving medication adherence. Dolutegravir/rilpivirine (DTG/RPV) was approved by the US Food and Drug Administration (FDA) as the first dual antiretroviral STR for the maintenance therapy of HIV-1 infection. Following an extensive review of all published papers on RPV and DTG, administered alone and in combination, extracted from databases including PubMed, Google scholar, and EMBASE, as well as drug package inserts and conference abstracts and proceedings, this review discusses the chemical properties and composition, pharmacodynamics and pharmacokinetic properties, clinical trial efficacy and safety data, as well as important drug–drug interactions associated with DTG/RPV. An expert opinion section discusses ideal candidates for DTG/RPV in the context of available but limited data and in comparison to currently available and emerging ART alternatives. Keywords: dolutegravir, rilpivirine, antiretroviral therapy, HIV

Keywords

• dolutegravir
• rilpivirine
• antiretroviral therapy
• HIV